EIF1B (eukaryotic translation initiation factor 1B) is a translation initiation factor involved in ribosomal small subunit binding and 43S preinitiation complex assembly 1. The protein exhibits RNA and protein binding activities essential for regulating translational initiation [GO annotations]. EIF1B demonstrates tissue-specific expression patterns across human tissues, suggesting specialized roles in translation regulation within differentiated cell types 1. This tissue-specific expression profile indicates that EIF1B may contribute to the diversification of translation machinery composition across organs and cell types. Clinically, EIF1B has emerged as a prognostic biomarker in cancer contexts. It was identified as one of 16 RNA-binding proteins associated with hepatocellular carcinoma (HCC) prognosis, with its dysregulation contributing to poor patient outcomes 2. Additionally, EIF1B was selected as a component of an eight-gene signature (UMPS) for predicting metastasis-free survival in uveal melanoma patients, demonstrating independent prognostic value 3. The gene's expression in tissues prone to metastatic involvement suggests potential roles in cancer tropism 4. These findings indicate that EIF1B dysregulation may contribute to cancer progression, making it a candidate therapeutic target and prognostic biomarker in multiple malignancies.